Eli Lilly Reports $6.45 Billion Third-Quarter Profit

The pharmaceutical company announced revenue of $24.4 billion during the third quarter of 2026.

Updated on Oct. 29, 2026 in Economic Indicators

Isometric editorial illustration of a sterile pharmaceutical manufacturing vessel, representing the scale of modern drug production. — Eli Lilly reported a $6.45 billion profit for the third quarter of 2026, with total revenue reaching $24.4 billion. AI Illustration. Upload story photo >

Live Poll

Does consistent pharmaceutical profit growth improve or hinder healthcare affordability for the average patient?

Eli Lilly and Co. reported a profit of $6.45 billion for the third quarter of 2026. The company reached a total revenue of $24.4 billion during the same period.

Why it matters

The company's strong quarterly performance highlights the current financial trajectory of major pharmaceutical firms. Investors are monitoring these figures as the company provides guidance for its annual financial goals.

Eli Lilly reported quarterly profit of $6.45 billion and revenue of $24.4 billion. Earnings per share reached $7.22, while adjusted earnings were reported at $7.48 per share.

The players

Eli Lilly and Co.

This global pharmaceutical company is headquartered in Indianapolis and develops a wide range of medical treatments.

The details

The Indianapolis-based company is maintaining its financial targets for the remainder of the year. Management issued forecasts expecting full-year earnings between $35 and $36 per share.

Eli Lilly released its financial results for Q3 2026 on October 29, 2026.

Macro View

The SEC quarterly reporting requirements mandate that companies like Eli Lilly disclose their financial health to the public, providing a standard benchmark for investor evaluation. This report follows the standard financial disclosure cycle required by federal regulatory oversight.

These quarterly earnings reports often influence market confidence and investor sentiment regarding the broader pharmaceutical sector. Shareholders and analysts use this data to gauge the financial stability of major health companies.

The takeaway

Financial disclosures help provide clarity on the fiscal health of major corporations for long-term planning. Investors should monitor how these quarterly results align with the company's full-year earnings projections.